

# Christopher L Amling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5534648/publications.pdf>

Version: 2024-02-01

80  
papers

1,794  
citations

361413

20  
h-index

302126

39  
g-index

80  
all docs

80  
docs citations

80  
times ranked

3143  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019, 5, 975.	7.1	288
2	Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	163
3	Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2349-2356.	2.5	111
4	Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy. <i>European Urology</i> , 2014, 65, 1171-1177.	1.9	110
5	Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 60-66.e2.	1.9	79
6	Timing, Incidence and Risk Factors for Venous Thromboembolism in Patients Undergoing Radical Cystectomy for Malignancy: A Case for Extended Duration Pharmacological Prophylaxis. <i>Journal of Urology</i> , 2014, 191, 943-947.	0.4	78
7	Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. <i>Genes and Development</i> , 2017, 31, 2067-2084.	5.9	57
8	Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. <i>Urology</i> , 2016, 96, 171-176.	1.0	55
9	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	7.1	49
10	Thresholds for <sup>sc</sup>PSA</sup> doubling time in men with nonmetastatic castration-resistant prostate cancer. <i>BJU International</i> , 2017, 120, E80-E86.	2.5	46
11	Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. <i>Journal of Urology</i> , 2016, 196, 1408-1414.	0.4	43
12	A natural history of weight change in men with prostate cancer on androgen deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. <i>BJU International</i> , 2011, 107, 924-928.	2.5	37
13	Obesity, race, and long-term prostate cancer outcomes. <i>Cancer</i> , 2020, 126, 3733-3741.	4.1	32
14	Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. <i>Cancer</i> , 2017, 123, 4199-4206.	4.1	30
15	Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. <i>Cancer Causes and Control</i> , 2018, 29, 581-588.	1.8	30
16	Prophylactic antibiotics following radical cystectomy reduces urinary tract infections and readmission for sepsis from a urinary source. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 238.e1-238.e5.	1.6	25
17	Racial Discrepancies in Overall Survival among Men Treated with <sup>223</sup> Radium. <i>Journal of Urology</i> , 2020, 203, 331-337.	0.4	25
18	Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 252-260.	3.9	24

#	ARTICLE	IF	CITATIONS
19	Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2017, 123, 1528-1535.	4.1	22
20	Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. <i>Prostate</i> , 2017, 77, 154-163.	2.3	22
21	Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (<sc>SEARCH</sc>) cohort. <i>BJU International</i> , 2016, 117, 244-248.	2.5	20
22	Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. <i>Cancer</i> , 2019, 125, 2861-2867.	4.1	20
23	Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. <i>Urology</i> , 2017, 108, 129-134.	1.0	17
24	Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy. <i>International Journal of Urology</i> , 2017, 24, 618-623.	1.0	16
25	Open versus robot-assisted radical cystectomy: 30-day perioperative comparison and predictors for cost-to-patient, complication, and readmission. <i>Journal of Robotic Surgery</i> , 2019, 13, 129-140.	1.8	16
26	Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 289.e11-289.e17.	1.6	16
27	In-Bore Versus Fusion MRI-Targeted Biopsy of PI-RADS Category 4 and 5 Lesions: A Retrospective Comparative Analysis Using Propensity Score Weighting. <i>American Journal of Roentgenology</i> , 2021, 217, 1123-1130.	2.2	16
28	Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 547-554.	2.5	15
29	Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. <i>Cancer</i> , 2017, 123, 4122-4129.	4.1	15
30	Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. <i>BJU International</i> , 2018, 122, 76-82.	2.5	15
31	Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. <i>Cancer</i> , 2019, 125, 4003-4010.	4.1	15
32	Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. <i>BJU International</i> , 2019, 124, 69-75.	2.5	15
33	Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. <i>International Journal of Urology</i> , 2018, 25, 998-1004.	1.0	13
34	Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab023.	2.9	13
35	Optimizing the Sequence of Chemotherapy for Upper Tract Urothelial Carcinoma with Clinically Positive Regional Lymph Nodes. <i>Journal of Urology</i> , 2019, 202, 76-82.	0.4	13
36	Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the <sc>SEARCH</sc> database. <i>BJU International</i> , 2016, 118, 250-257.	2.5	12

#	ARTICLE	IF	CITATIONS
37	First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 239.e17-239.e25.	1.6	12
38	Practice Patterns and Predictors of Followup Imaging after a Negative Bone Scan in Men with Castration Resistant Prostate Cancer: Results from the SEARCH Database. <i>Journal of Urology</i> , 2015, 193, 1232-1238.	0.4	11
39	In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. <i>European Urology Focus</i> , 2017, 3, 480-486.	3.1	11
40	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100070.	1.7	10
41	Deciding whom to biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 542-545.	1.6	9
42	Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy. <i>Journal of Urology</i> , 2020, 204, 511-517.	0.4	9
43	Validation of a bone scan positivity risk table in nonmetastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016, 118, 570-577.	2.5	8
44	Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer. <i>Cancer</i> , 2016, 122, 3848-3855.	4.1	8
45	Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. <i>Prostate</i> , 2017, 77, 1592-1600.	2.3	8
46	Time Trends in Use of Radical Prostatectomy by Tumor Risk and Life Expectancy in a National Veterans Affairs Cohort. <i>JAMA Network Open</i> , 2021, 4, e2112214.	5.9	8
47	Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?. <i>BJU International</i> , 2016, 117, 897-903.	2.5	7
48	Endorectal MR imaging of prostate cancer: Evaluation of tumor capsular contact length as a sign of extracapsular extension. <i>Clinical Imaging</i> , 2018, 50, 280-285.	1.5	7
49	Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. <i>Journal of Urology</i> , 2018, 199, 713-718.	0.4	7
50	Impact of Direct MRI-Guided Biopsy of the Prostate on Clinical Management. <i>American Journal of Roentgenology</i> , 2019, 213, 371-376.	2.2	7
51	Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e140-e149.	1.9	7
52	Protocol for GET FIT Prostate: a randomized, controlled trial of group exercise training for fall prevention and functional improvements during and after treatment for prostate cancer. <i>Trials</i> , 2021, 22, 775.	1.6	7
53	Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. <i>Cancer</i> , 2016, 122, 222-229.	4.1	6
54	Obese men undergoing radical prostatectomy: Is robotic or retropubic better to limit positive surgical margins? Results from SEARCH. <i>International Journal of Urology</i> , 2020, 27, 851-857.	1.0	6

#	ARTICLE	IF	CITATIONS
55	Survival outcomes and practice trends for off-label use of adjuvant targeted therapy in high-risk locoregional renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 604.e1-604.e7.	1.6	6
56	Association between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes among Patients with Intermediate and High-Risk Localized Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 592-600.	0.4	6
57	Agent Orange and long-term outcomes after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 329.e1-329.e6.	1.6	5
58	Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population. <i>Prostate</i> , 2021, 81, 390-397.	2.3	5
59	Red Blood Cell Distribution Width Is Associated with All-cause Mortality but Not Adverse Cancer-specific Outcomes in Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy: Findings Based on a Multicenter Shared Equal Access Regional Cancer Hospital Registry. <i>European Urology Open Science</i> , 2022, 37, 106-112.	0.4	5
60	Direct magnetic resonance imaging-guided biopsy of the prostate: lessons learned in establishing a regional referral center. <i>Translational Andrology and Urology</i> , 2017, 6, 395-405.	1.4	4
61	Unconventional Bladder Preservation: Factors Predicting Failure to Receive Definitive Surgery following Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer in the National Cancer Database. <i>Journal of Urology</i> , 2018, 200, 535-540.	0.4	4
62	An update on Society of Urologic Oncology fellowship programs. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 237-240.	1.6	3
63	Characterization of a low-risk cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database. <i>International Journal of Urology</i> , 2017, 24, 611-617.	1.0	3
64	The estimated prevalence of missed positive lymph nodes based on extent of lymphadenectomy at radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 574.e1-574.e9.	1.6	3
65	First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. <i>Cancer Causes and Control</i> , 2019, 30, 259-269.	1.8	3
66	Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. <i>Cancer</i> , 2019, 125, 3025-3032.	4.1	3
67	Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH. <i>Asian Journal of Urology</i> , 2019, 6, 242-248.	1.2	3
68	Does race predict the development of metastases in men who receive androgen deprivation therapy for a biochemical recurrence after radical prostatectomy?. <i>Cancer</i> , 2019, 125, 434-441.	4.1	3
69	Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer. <i>Cancer</i> , 2020, 126, 3274-3280.	4.1	3
70	Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. <i>Journal of Urology</i> , 2020, 203, 120-127.	0.4	3
71	Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study. <i>Prostate</i> , 2022, 82, 366-372.	2.3	3
72	Direct MRI-guided biopsy of the prostate: use of post-biopsy needle track imaging to confirm targeting. <i>Abdominal Imaging</i> , 2015, 40, 2517-2522.	2.0	2

#	ARTICLE	IF	CITATIONS
73	Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2016, 23, 241-246.	1.0	2
74	Providing Gender Confirmation Surgery at an Academic Medical Center: Analysis of Use, Insurance Payer, and Fiscal Impact. Journal of the American College of Surgeons, 2019, 229, 479-486.	0.5	2
75	Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes and Control, 2021, 32, 189-197.	1.8	1
76	Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy. Prostate Cancer and Prostatic Diseases, 0, , .	3.9	1
77	Editorial Comment. Journal of Urology, 2014, 191, 759-760.	0.4	0
78	Does salvage radiation therapy (SRT) change the biology of recurrent prostate cancer (PCa) based on PSA doubling times (PSADT)? Results from the SEARCH database. Journal of Clinical Oncology, 2012, 30, 203-203.	1.6	0
79	Reply by Authors. Journal of Urology, 2020, 203, 127-127.	0.4	0
80	Radium-223 Utilization Patterns and Outcomes in Clinical Practice. Urology Practice, 0, , .	0.5	0